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Introduction 
 
Up to 83% of Australians who are diagnosed with cancer use some form of complementary 
or alternative medicine or therapy (CAM)1, and the number of patients using CAMs 
alongside or (less commonly) instead of conventional treatment is increasing. 2-4 CAMs 
include physical, psychological, herbal, nutritional and spiritual therapies. Some are derived 
from traditional healing systems, and each has different risks and benefits. Cancer patients 
use CAMs for a variety of reasons: to help relieve symptoms of cancer and side-effects of 
conventional therapies; to enhance the efficacy of conventional treatments, to achieve a 
cure; to prolong life; to improve quality of life, or for personal or cultural reasons. 5-7 
Patients often decide to use CAMs without discussing this with health care professionals 
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who are providing standard care for many reasons, including because their health 
professionals often don’t ask.5, 8, 9,10 
 
While some CAMs have been shown to benefit patients with cancer, 6, 11-20 using CAMs 
whilst undergoing conventional treatments can pose significant risks, especially where the 
therapies are either oral or parenteral.10, 13, 15, 16, 20, 21  It is important therefore, that 
practitioners who administer conventional cancer treatments know about the risks and 
benefits of CAMs that are commonly used in their field of practice, and ask patients about 
their use of CAMs and ascertain how much they know about the risks and benefits of 
particular CAMs. Furthermore, CAM use should be monitored and recorded, and health 
services should have policies in place to address the use of CAMs by patients who are 
hospitalised or receiving outpatient care.  Refusing to acknowledge that patients use CAMs 
when they are receiving conventional medical care is unrealistic, and it can lead to 
significant harms arising from the CAMs themselves, from interactions between the CAMs 
and conventional therapies, or from failure to recognise where CAMs may be beneficial. 
With these concerns in mind, this survey was undertaken to examine the practices and 
policies surrounding the provision, prescription, and regulation of CAM within NSW cancer 
services. 
 
 
Materials and methods 
Participants 
All adult cancer services in urban, regional and remote areas of NSW (both public and 
private) were eligible for the survey. A list of 65 services was compiled using information 
from the Cancer Council Australia, the Cancer Institute of NSW, Cancer Council NSW and the 
Australian National Breast and Ovarian Cancer Centre (NBOCC). Palliative care services and 
paediatric haemato-oncology services were excluded. Respondents were either directors of 
cancer services, or other health professionals or administrators who were in a position to 
answer questions about CAM use and/or policies within each particular service.   
 
Survey 
The survey was a structured, self-administered questionnaire developed by the research 
team from a review of published studies of CAM, including empirical studies of CAM use in 
hospitals. Following development, the survey instrument was pilot-tested for face and 
content validity. The first section asked for basic information about the cancer service (e.g. 
whether it was located in public or private hospital, and whether it was in an urban, regional 
or remote location). The remainder was divided into five sections, each beginning with a 
“Key Question”:   
1. When patients are admitted or have their first consultation with your cancer 
service/hospital, is it expected that they will be asked about 
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complementary/alternative medicines they may be taking or complementary/ 
alternative therapies they may be receiving? 
2. Does your cancer service/hospital provide or prescribe any 
complementary/alternative medicines or therapies to haemato-oncology patients (in-
patients or out-patients)? 
3. Does your cancer service/hospital permit any CAM practitioners from the community 
(i.e. not employed by your hospital) to treat in-patients? 
4. Does your cancer service/hospital permit any in-patients to bring their own 
complementary medicines into the hospital? (e.g. herbal medicines, complementary 
dietary supplements). 
5. Does your cancer service/hospital have any formal policies about CAM?” 
 
Each key question was followed by a series of multiple-choice questions that probed for 
further information. Some questions also allowed free-text responses. 
 
Data collection 
The questionnaire was posted with a covering letter, two information sheets, and a pre-
paid, return-addressed envelope. After four weeks, non-responding services were sent a 
follow-up email with an electronic version of the survey attached, and a request to 
complete and return it by email, fax or post. After a further four weeks telephone calls were 
made to the contact at each institution that had not responded.  A final round of telephone 
calls was made at the end of March 2009.  
 
Analysis 
All returned surveys were de-identified and the data was entered in to SPSS22 for analysis. 
Descriptive statistics (i.e. counts and percentages) were obtained for all variables.  
 
Ethical approval 
The survey was approved by the University of Sydney Human Research Ethics Committee.   
 
 
Results 
Of the 65 eligible cancer services, 43 (66%) responded to the survey, 32 (74%) public and 11 
(26%) private. Almost half (n=21, 49%) were located in urban areas; 20 (46%) were located 
in regional areas and 2 (5%) were in remote areas. The distribution of non-responders was 
similar to that of responders by sector and location (Table 1). 
   
 
 
 
4 
Table 1. Comparison of responders and non-responders by sector and location 
 Urban Regional Remote Public Private Total 
Responders 21 (49%) 20 (47%) 2 (5%) 32 (74%) 11 (26%) 43 (100%) 
Non-responders 12 (55%) 10 (45%) 0 (0%) 16 (73%) 6 (27%) 22 (100%) 
 
Of the cancer services that responded to the survey, six (14%) indicated that they had 
formal policies about CAMs; 27 (63%) indicated that they had no formal policies, and in nine 
(21%) services, the respondent indicated that he or she did not know whether or not the 
service had any such policies.  
 
Cancer services enquiring about CAM use on initial contact 
In the majority of services (n=33, 77%), it was expected that patients were asked about their 
use of CAMs, either on admission to hospital and/or at first outpatient consultation. This 
proportion was higher in private services (10/11, 91%) compared to public services (23/32, 
72%). It was also higher in services located in urban hospitals (18/21, 86%) compared to 
those located in regional (14/20, 70%) and rural hospitals (1/2, 50%). 
 
Cancer services that provided or prescribed CAMs 
Of the 43 cancer services that responded to the survey, eight (19%) reportedly provided 
and/or prescribed CAMs for their patients. Of these, five were public, three were private, 
two were urban, five were regional and one was remote. Four of these eight services 
provided rooms or facilities for CAM practitioners to treat patients, and one cancer service 
had a dedicated CAM centre. This centre was located in a public, urban hospital, and 
provided services to in-patients, out-patients, lay carers and staff.  
 
The provision of CAMs was funded in a variety of ways. Two services charged patients for 
the services and/or products; two services were supported by hospital funding; two services 
were supported by donations from charitable organisations, and one service was supported 
by funding from the State Government.  
 
Most services reported that more than one group was involved in the administration and 
organisation of CAM services. Five centres nominated hospital nursing staff; three centres 
nominated allied health professionals, and two centres nominated both CAM professionals 
and volunteers.  
 
Three of the eight cancer services required CAM practitioners to be formally accredited by 
their relevant professional bodies. Formal credentials were not required in the services that 
employed either nursing or allied health professional staff as CAM practitioners. Individual 
liability insurance for CAM practitioners was required by two cancer services, but in other 
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cases the practitioners were covered by hospital insurance either as volunteers or as 
employees. 
 
Cancer services providing CAMs used a combination of methods to ensure patients were 
aware of this option, including information leaflets, hospital websites, posters, and informal 
advice from health professionals working within the cancer service.  One cancer service 
produced a DVD with information about CAM services, and one conveyed this information 
via hospital newsletter. The main reasons that informants gave for providing and/or 
prescribing CAMs were: patient well-being (seven services); patient demand (four services), 
respect for cultural beliefs (three services) and evidence of efficacy of selected CAMs (three 
services). 
 
Specific CAMs provided by the cancer services 
Four cancer services provided Massage Therapy, three services provided Aromatherapy, 
three provided Meditation and three provided Reiki. Qi Gong, Healing/Therapeutic Touch, 
Reflexology, Tai Chi, Art Therapy, Music Therapy and Indian Head Massage were provided 
by one service each. One service provided unspecified complementary medicines, and one 
provided “Supportive therapies whilst on chemotherapy, e.g.  Lactobacillus rhamnosus GG 
while on 5 Fluorouracil”. When asked why they provided or prescribed these particular 
CAMs, six services cited patient well-being, five cited evidence of safety, four cited efficacy 
of the CAM and patient demand, and two cited respect for cultural beliefs and practices. 
 
Recording CAM treatments in medical records 
In seven of the eight cancer services, details of CAMs that had been provided or prescribed 
by the cancer service were recorded by nursing staff in patient’s medical records. Five 
services recorded details for in-patients; five recorded details for out-patients, and three 
services recorded details for both in-patients and out-patients. One service also permitted 
CAM practitioners who were not employed by the hospital to make entries in their in-
patients’ hospital records. 
 
Treatment of in-patients by CAM practitioners from the community  
Only four cancer services permitted CAM practitioners from the community to treat in-
patients. One was located in a public hospital and three were located in private hospitals. All 
four services required medical or nursing staff to record details of CAM treatments in the 
patient’s hospital records, and one also permitted the CAM practitioner to do so. Three of 
these four cancer services placed restrictions on the CAM practitioners, requiring them to 
be hospital-approved, accredited, and have liability insurance. Two services further required 
the direct permission of medical staff for the CAM treatment.  
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Cancer services permitting in-patients to bring in their own CAMs 
Of the cancer services that responded to the survey, about half (n=24, 56%) permitted in-
patients to bring their own CAMs into hospital. One in five services (19% – two urban and six 
regional) did not know whether patients did this, and one in four services (26% – seven 
urban public, two urban private and two regional public) did not permit it.  
 
Medical approval of CAM use by in-patients 
Of the 24 services that allowed patients to bring their own CAMs into hospital, more than 
half (n=15, 63%) expected the treating doctor, or other medical professional staff, to 
routinely counsel the patient or guardian about their use of CAMs.  A majority of these 
services (n=17, 71%) also required that the treating doctor grant formal approval for each 
patient’s use of CAM whilst in hospital. Seven services permitted patients to continue using 
a CAM that their clinician had not approved. Only two of these services required that a 
notation be made in the patient’s records that the CAM was not approved for use. Three 
services required the completion of a “waiver of hospital responsibility form” or equivalent. 
 
Of the 17 services that required formal approval from the treating doctor for the use of 
CAMs by in-patients, 10 stated that the supply of unapproved CAMs was left to the patient; 
five were not sure who supplied unapproved CAMs, and 2 respondents did not answer this 
question. Only one cancer service assumed responsibility for storing the unapproved CAMs; 
the majority (11/17, 65%) left the responsibility for their storage to the patient. A majority 
(11/17, 65%) also reported that patients self-administered unapproved CAMs. Four 
respondents were uncertain as to who administered them. 
 
If the treating doctor sanctioned the use of a particular CAM, most of the 17 services (n=13, 
77%) documented its use in the patient’s hospital medication chart (six services) or in other 
specified locations including admission notes, medical records and nursing notes (five 
services). Approved CAMs were supplied by the patient in 12 of these 17 cancer services. 
One service was responsible for supply. Three cancer services were responsible for storing 
approved CAMs, and ten required the patient to store their own. Approved CAMs were self-
administered by the patient in most (11/17, 65%) services. Medical staff administered 
approved CAMs in two services, and nursing staff administered the CAMs in three services.  
 
Discussion 
The results of this survey indicate that the majority NSW cancer services are aware that 
many patients with cancer use CAMs or access CAM services. In the majority (77%) of 
responding NSW cancer services, it was expected that medical staff routinely ask patients 
about CAM use, and just over half (56%) of the services specifically permitted in-patients to 
use their own CAMs in hospital, with most informing patients of their ‘right’ to do so. 
However, while many services enquire about patients’ use of CAM, few demand formal 
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medical assessment of CAMs, or education of patients regarding the risks and benefits of 
using them. And of the cancer services that do allow patients to take their own CAMs while 
in hospital, few take responsibility for safe storage of the CAMs, and monitoring and 
recording of use is infrequent. 
 
There is evidence that some CAMs may provide benefits for patients with cancer by 
providing symptom relief, by reducing psychological distress and/or by improving well-
being. (6, 10-19) CAMs may also carry significant risks, however, either when used alone or 
when combined with conventional medical treatment. These risks include infection, 
fractures, bleeding, hepatic failure, adverse drug reactions and possibly tumour formation 
or recurrence. (12, 14, 15, 19-21) Yet the survey results reported above show that only a 
minority (17/43, 40%) of services required medical approval of in-patients’ CAM use whilst 
in hospital, and of these, less than half (7/17, 41%) documented the use of any unapproved 
CAM in medical records. The results also indicate that the supply, storage and administering 
of CAMs (both unapproved and approved) was largely unmonitored, and left mainly to the 
patient. 
 
This survey has a number of limitations. Firstly, it relies on self-reported data. Secondly, 
whilst the response rate (66%) is acceptable, it does leave room for selection bias (although 
it is reassuring that the demographic characteristics of non-responders were similar to 
responders as shown in Table 1). Thirdly, the absolute size of the sample was small, which 
obviated the use of statistical tests of significance in our analysis. Finally, we cannot be sure 
that each respondent was the ideal person to answer the survey questions.  
 
The findings of this survey are nevertheless important because they suggest that not 
enough attention is being paid to the monitoring and control of CAM use in NSW cancer 
services. This is concerning given that a significant number of patients with cancer use CAMs 
alongside their conventional treatment, that certain CAMs are associated with significant 
(and often uncertain) risks, and that there is a high likelihood of interaction between CAMs 
and conventional therapeutic agents.  In order to ensure that patients receive care that 
maximises benefit, minimises harm and is consistent with their values and life 
circumstances, then effective mechanisms to monitor and control CAMs need to be 
carefully considered, planned and widely implemented within both inpatient and outpatient 
haemato-oncology services. Given the complexity of this issue, it is likely that a number of 
policy and practice changes will be required. These should include, for example, policies that 
make it compulsory for hospital staff to ask patients about their use of CAM, to document 
CAM use in patients’ records, and to ensure safe storage of CAMs that patients bring into 
hospital. 
 
 
 
   
 
 
 
8 
References 
1. The cancer journey: Informing choice: Senate Community Affairs Committee, 
Parliament of Australia 2005; 23 June 2005. 
2. Senate Community Affairs References Committee. SENATE: Community Affairs 
References Committee: Service and treatment options for persons with cancer. Canberra 
2005; 12 May 2005. 
3. MacLennan AH, Myers SP, Taylor AW. The continuing use of complementary and 
alternative medicine in South Australia: costs and beliefs in 2004. Med J Aust 2006; 184(1): 
27-31. 
4. Broom A, Tovey P. Therapeutic pluralism? Evidence, power and legitimacy in UK 
cancer services. Sociology of Health and Illness 2007; 29(4): 551-569. 
5. Begbie SD, Kerestes ZL, Bell DR. Patterns of alternative medicine use by cancer 
patients. Med J Aust 1996; 165(10): 545-548. 
6. Correa-Velez I, Clavarino A, Eastwood H. Surviving, relieving, repairing, and boosting 
up: reasons for using complementary/alternative medicine among patients with advanced 
cancer: a thematic analysis. J Palliat Med 2005; 8(5): 953-961. 
7. Miller M, Boyer MJ, Butow PN, Gattellari M, Dunn SM, Childs A. The use of unproven 
methods of treatment by cancer patients. Frequency, expectations and cost. Support Care 
Cancer 1998; 6(4): 337-347. 
8. Newell S, RW S-F. Australian oncologists' self-reported knowledge and attitudes 
about non-traditional therapies used by cancer patients. Med J Aust 2000; 172(3): 110-113. 
9. Robotin MC, Penman AG. Integrating complementary therapies into mainstream 
cancer care: which way forward? Med J Aust 2006; 185(7): 377-379. 
10. Pirri C. Complementary and Alternative Medicine Use by Adult Cancer Patients: An 
Overview. In: Olver I, Robotin MC, editors. Perspectives on Complementary and Alternative 
Medicines. London: Imperial College Press; 2012. p. 439-459. 
11. Bulsara C, Ward A, Joske D. Haematological cancer patients: achieving a sense of 
empowerment by use of strategies to control illness.  2004; 13(2): 251-258. 
12. Cassileth BR. The Alternative Medicine Handbook: The Complete Reference Guide to 
Alternative and Complementary Therapies. New York: Norton; 1998. 
13. Cassileth BR, Deng G. Complementary and Alternative Therapies for Cancer.  2004; 
9(1): 80-89. 
14. Cheung CWY, Gibbons N, Johnson DW, Nicol DL. Silibinin – A Promising New 
Treatment for Cancer. Anti-Cancer Agents in Medicinal Chemistry 2010; 10(3): 186-195. 
15. Ernst E. A primer of complementary and alternative medicine commonly used by 
cancer patients Med J Aust 2001; 174: 88-92. 
16. Hatcher H PR, Cho J, Torti FM, Torti SV. Curcumin: from ancient medicine to current 
clinical trials. Cellular and Molecular Life Sciences 2008; 65(11): 1631-1652. 
   
 
 
 
9 
17. Joske DJ. Creating an Integrative Oncology Centre: The SolarisCare Experience. In: 
Olver I, Robotin MC, editors. Perspectives on Complementary and Alternative Medicines. 
London: Imperial College Press; 2012. p. 187-206. 
18. Joske DJ, Rao A, Kristjanson L. Critical review of complementary therapies in 
haemato-oncology. Internal Medicine Journal 2006; 36: 579-586. 
19. Rao A. Supporting Australians with cancer: A critical review of complementary 
therapies in oncology. Cancer Forum 2004; 28(2): 88-91. 
20. Rosenthal DS, Dean-Clower E. Integrative Medicine in Hematology/Oncology: 
Benefits, Ethical Considerations, and Controversies. Hematology: THe American Society of 
Hematology Education Program Book 2005; 2005(1): 491-497. 
21. Cassileth BR, Vickers, Andrew J. High Prevalence of Complementary and Alternative 
Medicine Use Among Cancer Patients: Implications for Research and Clinical Care (editorial). 
Journal of Clinical Oncology 2005; 23(12): 2590-2592. 
22. SPSS. PASW Statistics. 18th ed. Chicago: SPSS; 2009. 
 
 
 
 
 
